



DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD

An EGFR Targeted PET Imaging Probe for the Detection of Colonic Adenocarcinomas in the Setting of Colitis

The Harvard community has made this article openly available.
[Please share](#) how this access benefits you. Your story matters.

| | |
|--------------------------|---|
| Citation | Turker, N. Selcan, Pedram Heidari, Raju Kucherlapati, Melanie Kucherlapati, and Umar Mahmood. 2014. "An EGFR Targeted PET Imaging Probe for the Detection of Colonic Adenocarcinomas in the Setting of Colitis." <i>Theranostics</i> 4 (9): 893-903. doi:10.7150/thno.9425. http://dx.doi.org/10.7150/thno.9425 . |
| Published Version | doi:10.7150/thno.9425 |
| Accessed | February 16, 2015 4:21:03 PM EST |
| Citable Link | http://nrs.harvard.edu/urn-3:HUL.InstRepos:12717551 |
| Terms of Use | This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |

(Article begins on next page)

Research Paper

An EGFR Targeted PET Imaging Probe for the Detection of Colonic Adenocarcinomas in the Setting of Colitis

N. Selcan Turker¹, Pedram Heidari¹, Raju Kucherlapati², Melanie Kucherlapati², Umar Mahmood¹✉

1. Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA;
2. Department of Medicine/Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

✉ Corresponding author: Umar Mahmood, MD. PhD. Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA. Tel: 617-726-6477 Email: umahmood@mgh.harvard.edu.

© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (<http://creativecommons.org/licenses/by-nc-nd/3.0/>). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.

Received: 2014.04.17; Accepted: 2014.06.04; Published: 2014.07.01

Abstract

Colorectal cancer is a serious complication associated with inflammatory bowel disease, often indistinguishable by screening with conventional FDG PET probes. We have developed an alternative EGFR-targeted PET imaging probe that may be used to overcome this difficulty, and successfully assessed its utility for neoplastic lesion detection in preclinical models. Cetuximab F(ab')₂ fragments were enzymatically generated, purified, and DOTA-conjugated. Radiolabeling was performed with ⁶⁷Ga for cell based studies and ⁶⁴Cu for *in vivo* imaging. Competitive binding studies were performed on CT26 cells to assess affinity (K_D) and receptors per cell (B_{max}). *In vivo* imaging using the EGFR targeted PET probe and ¹⁸F FDG was performed on CT26 tumor bearing mice in both control and dextran sodium sulfate (DSS) induced colitis settings. Spontaneous adenomas in genetically engineered mouse (GEM) models of colon cancer were additionally imaged. The EGFR imaging agent was generated with high purity (> 98%), with a labeling efficiency of 60 ± 5% and ≥99% radiochemical purity. The K_D was 6.6 ± 0.7 nM and the B_{max} for CT26 cells was 3.3 ± 0.1 × 10⁶ receptors/cell. Target to background ratios (TBR) for CT26 tumors compared to colonic uptake demonstrated high values for both ¹⁸F-FDG (3.95 ± 0.13) and the developed ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ probe (4.42 ± 0.11) in control mice. The TBR for the EGFR targeted probe remained high (3.78 ± 0.06) in the setting of colitis, while for ¹⁸F FDG, this was markedly reduced (1.54 ± 0.08). Assessment of the EGFR targeted probe in the GEM models demonstrated a correlation between radiotracer uptake in spontaneous colonic lesions and the EGFR staining level *ex vivo*. A clinically translatable PET imaging probe was successfully developed to assess EGFR. The imaging agent can detect colonic tumors with a high TBR for detection of *in situ* lesions in the setting of colitis, and opens the possibility for a new approach for screening high-risk patients.

Key words: Positron emission tomography (PET) imaging, molecular imaging, EGFR, ulcerative colitis, colorectal cancer, mouse models.

Introduction

Inflammatory bowel disease (IBD), which consists of Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory condition that results from dysregulation of the mucosal immune system in the gastrointestinal tract¹. The incidence of IBD is increasing, and 1.4 million people in the United States

and 2.2 million people in Europe are affected by the disease². Colorectal cancer (CRC) is one of the most serious complications of IBD involving the colon, and is responsible for 10-15% of IBD deaths. CRC is curable at the early stages and early detection of CRC or colonic adenomas resulting from chronic inflamma-

tion is a major focus of current research studies to improve patient survival³. Endoscopic guided biopsy is the standard for the diagnosis of CRC and periodic colonoscopy examinations reduces the mortality risk in IBD-associated CRC⁴. However, the issues surrounding endoscopic screening are exacerbated in ulcerative colitis (UC), in which dysplasia can develop in macroscopically normal-appearing mucosa⁵. Current colonoscopic surveillance in UC patients relies on random biopsies throughout the colon, which is a relatively insensitive and cumbersome strategy that is not widely utilized⁶. Because periodic screening is essential to reduce the incidence of IBD-associated CRC, the development of better molecular imaging technologies to detect CRC in the setting of colitis could provide a new approach for screening in this setting.

Positron emission tomography (PET) is of considerable importance to clinicians in the staging and treatment planning in patients with CRC⁷. ¹⁸F-Fluorodeoxyglucose (FDG) is a glucose analog that is the most widely employed PET radioligand in oncology, given the increased glycolysis rate often observed in tumors. However, inflammatory cells are also glycolytically active⁸, and ¹⁸F FDG has been used to monitor the degree of active inflammation in IBD⁸⁻¹⁰. Improved differentiation between neoplastic and nonneoplastic lesions is important in target selection for molecular imaging¹¹. Detection of the increased glycolytic activity of CRC in the setting of increased glycolytic activity seen in IBD may result in a poor target to background ratio (TBR) for ¹⁸F-FDG.

We hypothesized that highly expressed epitopes on CRC tumor cells may provide an alternative target for imaging in this setting. We noted that epidermal growth factor receptor (EGFR) overexpression is present in approximately 80% of CRC cases, correlated with poor prognosis, decreased survival, and early recurrence¹². While EGFR overexpression by itself does not directly result in utility as a therapeutic target, based in part on downstream K-RAS and additional signaling requirements¹³, the high rate of overexpression may be exploited as a target for lesion detection¹⁴. Inflammatory cell lineages do not overexpress EGFR, and thus in the setting of colitis, imaging based on EGFR expression may result in high TBR for detection of in situ cancer¹⁵. We developed a novel EGFR targeted PET imaging agent and tested the probe to assess radioligand uptake in colon cancer allografts, spontaneous colonic adenomas in genetically engineered mouse models, and in chemically induced colitis. We compared the TBR for allografts and colitis for the EGFR targeted probe relative to ¹⁸F-FDG.

Materials and Methods

Preparation of F(ab')₂ fragments

Cetuximab F(ab')₂ fragments were prepared by specific enzymatic digestion using a FragIT™ Micro-Spin column (Genovis, Lund, Sweden) and the crude digest was purified by an immobilized NAb™ Protein A spin column (ThermoScientific Sci, Rockford, IL, USA) to remove the Fc fragment. The purity of cetuximab-F(ab')₂ was assessed with sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on a 4-15% Mimi-PROTEAN® TGX mini-gel (Bio-Rad, Mississauga, ON, Canada) and with fast protein liquid chromatography (FPLC). F(ab')₂ was electrophoresed under non-reducing conditions with SDS-PAGE and the gel was stained with Bio-Safe™ Coomassie G-250 stain (Bio-Rad, Mississauga, ON, Canada). FPLC was performed on a HIPREP™ 26/60 Sephacryl™ S-200 HR column (GE Healthcare Bio-Sciences AB, Björkgatan, Uppsala, Sweden) and eluted with 100 mM NaH₂PO₄ buffer (pH 7.0) at a flow rate of 1.2 mL/min at 280 nm. Trace metals were removed from all buffers using Chelex®-100 cation-exchange resin (Sigma-Aldrich, Saint Louis, MO, USA). Cetuximab-F(ab')₂ fragments were concentrated and buffer-exchanged into 0.1 M HEPES buffer, pH 8.9 on an Amicon Ultracel 30 K device (MWCO=30 kDa; EMD Millipore Corporation, Billerica, MA, USA)¹⁶. Cetuximab-F(ab')₂ was conjugated with the bifunctional 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (p-SCN-Bn-DOTA, Macrocyclics, Inc., Dallas, TX, USA) chelate in anhydrous DMSO by a modification of established methods using 10 fold molar excess of chelate to cetuximab F(ab')₂^{17, 18}. Conjugation was allowed to proceed overnight at 2–8 °C. DOTA-cetuximab-F(ab')₂ was purified from excess DOTA by the Amicon Ultracel 30 K device with 0.25 M ammonium acetate buffer (pH 6.0) and centrifuging at 3500 rpm for 10 min. This purification step was repeated six times. Finally, purified DOTA-cetuximab-F(ab')₂ was recovered and the concentration determined spectrophotometrically [E₂₈₀ nm = 1.45 (mg/mL)⁻¹ cm⁻¹]¹⁹. The final concentration was adjusted with 0.25 M ammonium acetate buffer (pH 6.0) for aliquoting.

The DOTA substitution level of the F(ab')₂ fragments (chelators/molecule) was measured by labeling a 10 μL aliquot of the unpurified conjugate with ⁶⁷Ga and then determining the proportion of ⁶⁷Ga-DOTA-cetuximab-F(ab')₂ vs. free ⁶⁷Ga-DOTA by ITLC-SG and multiplying this fraction by the molar ratio used in the reaction¹⁹.

Radiolabeling procedures

Radiolabeling was done with ^{67}Ga (MDS-Nordion, Kanata, Canada) or ^{64}Cu (University of Wisconsin, Madison, WI) as described previously^{20,21}. We used ^{67}Ga for cell binding assays due to its relatively longer half-life (3.26 d) in comparison with ^{64}Cu (0.529 d) and lower energy, facilitating the cell study workflow. Briefly the ^{67}Ga radioisotope (1–5 mCi) was added to the conjugate (50–100 μg) dissolved in 10 mM sodium acetate buffer (pH 4.5) and then incubated at 40°C for 90 min. ^{64}Cu radiolabeling was performed by incubating 50–100 μg of DOTA-cetuximab-F(ab')₂ in 0.25 M ammonium acetate buffer (pH 6.0) with $^{64}\text{CuCl}_2$ for 90 min at 40°C with constant shaking. The $^{67}\text{Ga}/^{64}\text{Cu}$ -radiolabeled compounds were purified from free $^{67}\text{Ga}/^{64}\text{Cu}$ and other low molecular weight impurities on an Amicon Ultracel 30 K device. The purity of the labeled compounds were checked by size exclusion chromatography using a PD-10 Desalting Column (GE Healthcare Bio-Sciences AB, Björkgatan, Uppsala, Sweden) eluting with phosphate-buffered saline (PBS) as the mobile phase. The two different isotopes were used for *in vivo* and *in vitro* studies, in order to more closely match the isotope half-lives with the differences in length of the respective studies.

Cell culture

CT26 murine colorectal carcinoma and HCT-116 human colorectal carcinoma were obtained from the American Type Culture Collection (ATCC). They were cultured in RPMI and McCoy's 5a Medium (ATCC) and supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin, and 100 $\mu\text{g}/\text{mL}$ streptomycin respectively. The cells were maintained in a humidified atmosphere of 5% CO_2 at 37 °C.

Competitive binding studies

The EGFR binding affinity of ^{67}Ga -DOTA-cetuximab-F(ab')₂ was determined by direct (saturation) radioligand binding assays in triplicate using a fixed concentration of cetuximab and increasing concentration of ^{67}Ga -DOTA-cetuximab-F(ab')₂ on the CT26 cell line with slight modification of previous studies²². Briefly, increasing concentrations (0 to 100 nmol/L) of ^{67}Ga -DOTA-cetuximab-F(ab')₂ was incubated with 1×10^5 cells in 24-well plates at 4°C for 3 hr. Unbound radioactivity was removed and the dishes were rinsed three times with ice cold PBS and cells detached with 0.05% trypsin. The number of cells in each well was counted using an automated cell counter (Countess®, Invitrogen, NY, USA) and the total cell-bound radioactivity (TB) was measured in a gamma counter (Wizard 2480, Perkin Elmer, MA,

USA). The assay was repeated in the presence of 16 $\mu\text{mol}/\text{L}$ of unlabeled cetuximab to measure non-specific binding (NSB) at 4°C for 2h. Specific binding (SB) was calculated by subtracting NSB from TB and was plotted vs. the concentration of ^{67}Ga -DOTA-cetuximab-F(ab')₂ added. The resulting curve was fitted by non-linear regression to a one-site receptor-binding model by Prism software (GraphPad, San Diego, CA, USA). The dissociation constant (K_D) and maximum number of receptors per cell (B_{max}) was calculated.

Western Blot Analysis

In order to ensure EGFR expression in CT26 and HCT-116 cells, Western blot analysis was carried out as previously described²³. EGFR expression level of CT26 was compared with the high EGFR expressing HCT116 human colon cancer cell line. Briefly, EGFR and beta-actin were detected with EGFR receptor XP rabbit mAb (Cell Signaling, Danvers, MA, USA) (1:1000 dilution) and beta-actin rabbit mAb (Cell Signaling, Danvers, MA, USA) (1:1000 dilution). Then the proteins were incubated with goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and detected using the BM chemiluminescence Western blotting kit (Roche Diagnostics, Indianapolis, IN, USA) and bands were visualized with a Kodak *in vivo* FX PRO system (Carestream Health, New Haven, CT, USA).

Animal models

All animal experiments were approved by our Institutional Animal Care Committee. Mice were maintained with free access to standard chow and water. Female BALB/c mice (6 weeks old, with a body weight of 18–20 g) were purchased from Charles River Laboratories International Inc. Dextran Sulfate Sodium (DSS)-treated mice were prepared by the administration of 3.0% DSS (mol wt 40,000–50,000, MP Affymetrix, Inc., Cleveland, Ohio, USA.) in drinking water for seven days, followed by a regimen of three days of normal drinking water, as described previously²⁴. Control mice received water *ad libitum*. Fresh DSS solutions were prepared daily and mice were recorded daily for the body weight loss, which was calculated relative to day 0. Subcutaneous (s.c) CT26 tumors were established in a subset of BALB/C mice by s.c injection of 100 μL (10^6 cells) of CT26 cell suspension in Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) in the right upper flank.

To further assess the imaging method, mice with conditional knockout (CKO) mutant alleles were generated as previously described^{25, 26, 27, 28} and $Apc^{\text{CKO}p53^{\text{flox/flox}}}$ and $Apc^{\text{LoxP}/\text{LoxP}}Msh2^{\text{null}/\text{LoxP}}$ mutant mouse models were used to evaluate the imaging

potential of ^{64}Cu -DOTA-cetuximab-F(ab')₂ in CRC.

PET/CT imaging protocol

Before imaging with ^{18}F -FDG, the mice were kept fasted for 4 hr and allowed free access to water. For PET/CT imaging, approximately 400 μCi of ^{18}F -FDG or 100 μCi of ^{64}Cu -DOTA-cetuximab-F(ab')₂ in a final volume of 200 μl was injected to each mouse via the tail vein under 2% isoflurane gas anesthesia.

PET data were acquired using a whole-body emission protocol on an Argus small-animal PET/CT scanner (Sedecal, Madrid, Spain) for 15 min in 2 bed positions 1 hr after ^{18}F -FDG and 24 hr after ^{64}Cu -DOTA-cetuximab-F(ab')₂ injection under gas anesthesia with 1.5% isoflurane. Images were reconstructed with a 2D ordered-subset expectation maximization (2D-OSEM) algorithm (2 iterations, 16 subsets, with scatter and randoms corrections). CT data were acquired in standard resolution. The scan parameters were set as follow: tube voltage 40 kVp, tube current 140 μA , number of projections 360, number of shots 8, axial field-of-view 80 mm. Scans were recorded without respiratory gating. Total scan duration was approximately 14 min. Image data were reconstructed using FeldKemp algorithm. Three-dimensional regions of interest (ROI) were manually drawn around tumors based on co-registered CT scans acquired immediately after PET imaging. Mean standardized uptake values (SUVs) were calculated within the ROI.

Antibody blocking studies

Blocking studies were carried out to evaluate EGFR specificity of ^{64}Cu -DOTA-cetuximab-F(ab')₂ *in vivo*. Mice bearing CT26 allografts (n=4) were each intravenously injected with 1.5 mg of cetuximab 24 hr before ^{64}Cu -DOTA-cetuximab-F(ab')₂ administration. The control group mice with CT26 allografts (n=4) were injected with intravenous PBS 24 hr before ^{64}Cu -DOTA-cetuximab-F(ab')₂ injection. ^{64}Cu -DOTA-cetuximab-F(ab')₂ was intravenously injected into each mouse under isoflurane anesthesia and static PET/CT scans were acquired at 24 hr post injection. Mean standardized uptake values (SUVs) of the allografts were calculated and compared between groups.

PET/CT imaging with ^{18}F -FDG and ^{64}Cu -DOTA-cetuximab-F(ab')₂

PET was performed to quantitate the effect of intestinal inflammation upon bowel ^{18}F -FDG uptake, as measured in BALB/c mice induced with DSS. ^{18}F -FDG was purchased from IBA. A baseline ^{18}F -FDG PET/CT was performed on day 0 to ensure that the subject mice have no baseline bowel pathology that enhanced glucose uptake.

The DSS-treated (n=4) and control mice (n=4) with CT26 s.c. allografts were imaged with ^{18}F -FDG and ^{64}Cu -DOTA-cetuximab-F(ab')₂ PET/CT and tumor to bowel ratios were compared between the DSS-treated mice and control group for both radiotracers (^{18}F -FDG and ^{64}Cu -DOTA-cetuximab-F(ab')₂).

Conditional knockout mice with *Apc*^{CKOp53^{flox/flox}} and *Apc*^{LoxP/LoxP}*Msh2*^{null/LoxP} mutation underwent whole body PET/CT imaging 24 hr after intravenous ^{64}Cu -DOTA-cetuximab-F(ab')₂ injection. The colons of the mice were extracted immediately after whole body PET/CT and were placed in the PET/CT scanner for ex vivo imaging. The static ex vivo PET/CT images from these colons were overlaid on the gross white light photographs of the colons in the same position and orientation.

Histological analysis

Mice were euthanized and the colons were removed, and cleaned in physiological saline solution to remove fecal residue. They were fixed in neutrally buffered 10% formalin at room temperature for 48 hr before they were embedded in paraffin and sectioned. All tissues were stained with hematoxylin and eosin (H&E) for histological evaluation. Light microscopy was performed with an Olympus IX51 microscope.

Immunohistochemical (IHC) analysis was performed on CT26 tumor allografts, and colon tissue samples as described previously^{1,7}. Briefly, unstained 5 μm sections were cut, deparaffinized and rehydrated by standard techniques before antigen retrieval in EDTA buffer. The samples were then incubated in a 1:50 dilution of anti-EGFR rabbit polyclonal IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) overnight at 4 °C. The sections were washed in TBST and incubated with biotinylated goat anti-rabbit IgG (H+L) (Abcam, Cambridge, MA, USA) for 1 hr. The staining was developed using the DAKO Liquid DAB + substrate chromogen system (Dako, Carpinteria, CA, USA) for 1 min. Slides were washed in water and counterstained with hematoxylin and dehydrated before mounting.

Statistics

Statistical analysis was performed using Prism software (Graphpad, San Diego, USA). Differences in uptake of the tracers were tested for significance using the t-test. P-values of 0.05 were considered significant. Data are represented as mean \pm standard error of the mean (SEM).

Results

Radiotracer preparation and characterization

F(ab')₂ fragment of cetuximab was produced through enzymatic digestion as shown in Figure 1A.

F(ab')₂ was generated with high purity (> 98%) and 1.2 mg F(ab')₂ was recovered from 2 mg of antibody (~60% yield). The size-exclusion FPLC and SDS-PAGE results demonstrated that pure F(ab')₂ fragment of cetuximab was obtained after the digestion of intact IgG with enzymatic digestion and followed by protein A purification (Figure 1B&C). Whole antibody appears at 180 min, while F(ab')₂ appears at 202 min and Fc appears at 235 min (Figure 1B). Reaction of cetuximab F(ab')₂ with a 10-fold excess of p-SCN-Bn-DOTA resulted in substitution of approximately 1 DOTA chelate per F(ab')₂. The labeling efficiency for ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ was 60 ± 5% and with ≥99% radiochemical purity (Figure 1D). The specific activity of ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ was 19.5 ± 6.8 mCi/mg cetuximab.

We observed that CT26 murine colon cancer cell line has high EGFR expression, comparable to that of high EGFR expressing HCT-116 human colorectal cancer line as shown in Western blot analysis (Figure 1F). Direct (saturation) radioligand binding assays

showed that ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ bound specifically to EGFR on CT26 cells (Figure 1E). The K_D value for ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ was 6.6 ± 0.7 nM and the B_{max} value on CT26 cells was 3.3 ± 0.1 × 10⁶ receptors/cell. A representative competitive binding curve of ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ is shown in Figure 1E.

The ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ is specific for EGFR *in vivo*

The specificity of ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ for EGFR was confirmed by *in vivo* blocking studies (Figure 2). Administering a blocking dose of cetuximab the tumor uptake was significantly reduced (SUV of 0.31 ± 0.04 (non-blocking) vs. 0.15 ± 0.02 (blocking), n=4; P<0.05) and (tumor to muscle SUV of 6.64 ± 0.85 (non-blocking) vs. 2.56 ± 1.87 (blocking), n=4; P<0.05) which demonstrated that ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ maintained EGFR specificity *in vivo*.




Figure 1. A schematic overview of the EGFR targeted PET probe synthesis and characterization. (A) Enzymatic fragmentation of whole antibody and conjugation of F(ab')₂ fragment with bifunctional chelator. (B) FPLC chromatograms of whole IgG before digestion, after digestion, and after protein A purification. (C) SDS-PAGE analysis of enzymatic digestion of cetuximab IgG. (i) Whole antibody before digestion; (ii) F(ab')₂ and Fc bands after digestion of whole antibody; (iii) F(ab')₂ band after protein A purification. (D) Radiolabeling and purification of F(ab')₂-DOTA conjugate with ⁶⁷Ga. (E) Direct (saturation) radioligand binding to CT26 murine colorectal cancer cells of ⁶⁴Cu-DOTA-cetuximab-F(ab')₂, in the absence (total binding; TB) or presence (non-specific binding; NSB) of excess (× 20 times) unlabeled cetuximab IgG. Specific binding (SB) was calculated by subtraction of NSB from TB. Curves were fit to a 1-site receptor-binding model. ◆ = TB; ■ = NSB; ▲ = SB. (F) Western blot of EGFR expression in CT26 and HCT-116 colon cancer cell lines with beta-actin as control, demonstrate EGFR overexpression.




Figure 2. PET imaging of EGFR expression in BALB/c mice at 24 hr post injection of ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ or ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ after treatment with a 1.5 mg blocking dose of cetuximab. A) Example images without and with blocking. Red circles highlight site of implanted CT26 tumor allograft B) Comparison of MeanSUV values of ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ without and with blocking. Each bar represents SUVmean ± SEM; n=4 for each group, and the symbol * denotes P<0.05. C) Comparison of tumor to muscle ratios of ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ without and with blocking. Each bar represents SUVmean ± SEM; n=4 for each group, and the symbol * denotes P<0.05.

The DSS induced colitis model

Body weight loss was used to monitor colitis. The body weight loss gave a peak on day 8 (Figure 3A). The body weight was significantly decreased (23.35 ± 0.11 g (day 0) vs. 20.45 ± 0.64 g (DSS-treated, day 8) and 23.35 ± 0.11 g (day 0) vs. 20.35 ± 0.21 g (DSS-treated, day 10), n=4, P<0.05) after DSS treatment. PET imaging was performed on control and DSS-treated mice to assess the effects of colitis on ¹⁸F-FDG colonic uptake after DSS treatment. The arrows on the images indicate the high characteristic accumulation of ¹⁸F-FDG in the inflamed areas of DSS-treated mice (Figure 3B). ¹⁸F-FDG PET/CT scans showed significant increase in uptake (0.22 ± 0.02 %ID/g (control) vs. 0.43 ± 0.09 %ID/g (DSS-treated, day 9), n=4, P<0.05) in the colons of the DSS-treated groups.

Histological examination of the normal colon showed normal mucosal architecture. Mucin loss, loss

of crypt architecture and intraepithelial inflammation was observed in the colon of mice that received DSS treatment for seven days (Figure 3C).

PET/CT imaging

In a subset of control and DSS-treated BALB/C mice implanted with CT26 allografts imaging was performed sequentially with both ¹⁸F-FDG and ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ to compare the tumor to bowel radiotracer uptake ratios (Figure 4A). The tumor to bowel ratio was significantly decreased (3.95 ± 0.13 (control) vs. 1.54 ± 0.08 (DSS-treated), n=4, P<0.05) in DSS-treated mice imaged with ¹⁸F-FDG. However there was no significant difference (4.42 ± 0.11 (control) vs. 3.78 ± 0.06 (DSS-treated), n=4, P=0.22) in the tumor to bowel ratio between the control and the DSS-treated mice imaged with ⁶⁴Cu-DOTA-cetuximab-F(ab')₂. ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ also showed significantly higher (3.78 ± 0.06 (⁶⁴Cu-DOTA-cetuximab-F(ab')₂) vs. 1.54 ± 0.08

(^{18}F -FDG), $n=4$; $P<0.05$) tumor to bowel ratio in comparison with ^{18}F -FDG in DSS-induced mice (Figure 4B).

^{64}Cu -DOTA-cetuximab-F(ab')₂ whole body PET/CT images of mice with $Apc^{\text{CKO}P53^{\text{flox/flox}}}$ and $Apc^{\text{LoxP/LoxP}Msh2^{\text{null/LoxP}}}$ mutations revealed focal areas of high uptake in colonic adenomas. After the PET/CT imaging, the colons were excised and imaged ex vivo with PET/CT. An anatomic correlation between the location of visible adenoma foci and areas of high uptake in ex vivo ^{64}Cu -DOTA-cetuximab-F(ab')₂ PET/CT images was noted. (Figure 5A&B).

Histopathologic analysis

H&E and IHC stained tissue sections of mice are shown in Figure 6. Normal colonic mucosa with crypt architecture, along with modulation seen with DSS-treatment, and characteristic features in the adenomas are noted (Figure 6A). Membranous brown staining of cells above the background level was defined as EGFR positive. IHC staining for EGFR revealed very weak staining in control and DSS-treated colonic tissue, while strong EGFR staining was observed with CT26 allograft and colon tumors from $Apc^{\text{CKO}p53^{\text{flox/flox}}}$ and $Apc^{\text{LoxP/LoxP}Msh2^{\text{null/LoxP}}}$ mutant mice (Figure 6B). Interestingly, the level of IHC staining for EGFR for the adenomatous lesions visually corresponds with the level of vivo ^{64}Cu -DOTA-cetuximab-F(ab')₂ uptake in the ex vivo samples (Figure 5).




Figure 3. Assessment of symptoms and histological findings of DSS-treated and control mice. BALB/c mice were subjected to 3% DSS for seven days and followed with normal drinking water for three days. (A) Body weight changes following DSS induction of colitis, reported as mean \pm SEM ($n=4$ mice/group) and the symbol * denotes $P<0.05$. (B) microPET-CT scans were obtained before and after DSS treatment. Before DSS treatment, PET showed only low level of physiologic ^{18}F -FDG uptake in the colon of healthy controls. In contrast, on day nine, clearly elevated ^{18}F -FDG colonic uptake is noted (red arrow). (C) Histological appearance of the normal colonic mucosa of healthy controls with intact crypts and architecture (control) and DSS-induced colitis showing inflammatory infiltration (arrow head), mucin loss (arrow) and crypt architectural disarray (dashed arrow). Magnification $\times 20$ and scale bar represents 100 μm .




Figure 4. Comparison of PET imaging with ^{18}F -FDG and ^{64}Cu -DOTA-cetuximab-F(ab')₂ in CT26 tumor-bearing mice with and without DSS-induced colitis. (A) PET-CT images were performed 1 hr after ^{18}F -FDG and 24 hr after ^{64}Cu -DOTA-cetuximab-F(ab')₂ administration. Representative images from a mouse are shown, with $n=4$ mice imaged in each group. Red squares indicate the location of tumors and blue squares indicate location of DSS-induced colitis. (B) Comparison of tumor to colon ratios at 24 hr post-injection. Each bar represents SUVmean \pm SEM; $n=4$ for each group. The symbol * denote $P < 0.05$ and the difference is not significant ($P = 0.22$) for ^{64}Cu -DOTA-cetuximab-F(ab')₂. The dash line verifies TBR=1 (no contrast).

Discussion

Persistent inflammation in the colon seen in IBD is correlated with increased cell proliferation, dysplasia, and the subsequent development of CRC^{4, 29-31}. The mortality of IBD associated CRC has remained high over the last 20 years, in part due to the approximately 50% of CRC that were not detected until an advanced stage³². Therefore there is a clear need to develop new screening strategies that are more sensitive and less cumbersome than current approaches for high-risk patients. While the noninvasive nature of PET scanning greatly improves tolerance, colonic inflammation that is a hallmark of IBD affecting the colon makes noninvasive screening for cancer using ^{18}F -FDG PET somewhat less useful in the IBD setting, given the known uptake of the radiotracer in inflammatory as well as neoplastic cells. We hypothesized that EGFR would be an appropriate target for imaging, highlighting tumor even in the setting of colitis, given its high expression seen in the large majority of CRC, and the lack of overexpression noted in normal colonic mucosa and in the inflammatory cells associated with chronic colitis. We thus developed an EGFR targeting PET imaging agent based on the F(ab')₂ fragment of cetuximab conjugated to the chelator DOTA and labeled with the radiometal ^{64}Cu . We chose the F(ab')₂ fragments as the basis for the imaging agent given the improved target to background ratio (TBR) relative to whole antibodies³³, and im-

proved pharmacokinetics for translation^{16, 34}. The developed imaging agent is translatable for human studies given the high safety profile of the parent antibody, and the components have all been utilized in prior clinical translation. PET imaging agents have an advantage of an extremely low mass of injection given the high sensitivity of PET detection, and thus a broad range of agents have been translated to human evaluation³⁵. Finally, as new algorithms are developed for image reconstruction and with the introduction of PET-MR clinical scanners, the radiation dose associated with PET imaging continues to decrease, making this potential approach more appealing³⁶. While very low bowel uptake was seen in these preclinical studies in both normal and colitis settings, given the known hepatic clearance, early translational studies will help confirm that low signal from bowel remains in the clinical setting.

Monoclonal antibodies are widely used as therapeutics. However, their long circulation time typically in the range of days to weeks, and the potential for immune response, make their use as imaging agents less ideal³⁷⁻³⁹. Bivalent F(ab')₂ antibody fragments have a shorter blood clearance, higher tumor to background ratios at early time points, reduced non-specific distribution, and lower immunogenicity relative to whole antibodies, while retaining the advantage of increased affinity associated with bivalency^{16, 40}. The developed imaging probe has a high

affinity of 6.6 nM for EGFR. We chose a radioisotope, ^{64}Cu ($t_{1/2} = 12.7$ h), that matched the pharmacokinetics of the F(ab')₂ antibody fragment³⁹. We demonstrated that the EGFR targeting probe was able to image both allografts (CT26 tumors) as well as spontaneous colonic adenomas in two different GEM models (*Apc*^{CKO}*p53*^{lox/flo} and *Apc*^{LoxP/LoxP}*Msh2*^{null/LoxP})²⁵⁻²⁸ with high standard uptake values (SUV). In the previous studies, Western blots of EGFR expression on human and murine cell lines showed that cetuximab strongly binds to the murine cell line CT26⁴¹. GEM models are selected to provide a platform for studying CRC from certain mutations such as *Apc* and *p53*. *Apc*^{CKO}*p53*^{lox/flo} and *Apc*^{LoxP/LoxP}*Msh2*^{null/LoxP} GEM models were selected

for this study because *Apc* and *Msh2* processes are often deranged in large numbers of CRCs in the setting of IBD^{42, 43}. The EGFR targeted probe uptake in spontaneous lesions in representative mouse models of colonic adenomas further points to the translational potential of this approach. Both ^{18}F -FDG and ^{64}Cu -DOTA-cetuximab-F(ab')₂ demonstrated high TBR for tumor uptake relative to normal colon. However, the EGFR targeting probe retained a high TBR in the setting of colitis, whereas the TBR markedly decreased for ^{18}F -FDG to approximately 1.5 in the setting of bowel inflammation, largely due to the expected increase in ^{18}F -FDG uptake in the inflamed bowel.




Figure 5. Correlation between EGFR targeted PET imaging and EGFR immunohistochemistry. (A1) PET imaging of *Apc*^{CKO}*p53*^{lox/flo} mouse with ^{64}Cu -DOTA-cetuximab-F(ab')₂ at 24 hr. (A2) The digital photograph of colon and the colon fused with the ex-vivo PET image. (A3) Corresponding EGFR expression patterns of different colon sections numbered in A2 are confirmed with immunohistochemistry (magnification $\times 20$). (B1) Representative images of decay corrected PET image of *Apc*^{LoxP/LoxP}*Msh2*^{null/LoxP} mutant mice after the injection of ^{64}Cu -DOTA-cetuximab-F(ab')₂ at 24 hr. (B2) The digital photograph of colon and the colon fused with the ex-vivo PET image. (B3) EGFR expression patterns of different colon sections numbered in B2 are confirmed with immunohistochemistry (magnification $\times 20$). Scale bar represents 50 μm .




Figure 6. H&E and IHC analysis were examined to compare the histological changes in colons from healthy, DSS-treated, GEM models and allograft (CT26 tumor). IHC results demonstrate that there is no significant EGFR expression in healthy and DSS-treated colons, while there is strong staining in allograft and GEM model colonic lesions. (A) Representative H&E tissue sections from (a1) healthy colon, (a2) DSS-treated colon, (a3) CT26 allograft, (a4) *Apc^{CKOP53^{fllox/fllox}}* mutant mouse colon, (a5) *Apc^{LoxP/LoxP/Msh2^{null/LoxP}}* mutant mouse colon. (B) IHC analysis of EGFR from tissues of (b1) healthy colon, (b2) DSS-treated colon, (b3) CT26 allograft, (b4) *Apc^{CKOP53^{fllox/fllox}}* mutant mouse colon, (b5) *Apc^{LoxP/LoxP/Msh2^{null/LoxP}}* mutant mouse colon. Scale bar represents 50 μ m.

A large percentage of IBD-associated cancers have immunohistochemical positivity for EGFR and strong EGFR intensity has been associated with higher tumor staging^{44, 45, 46}. Our results show a strong correlation between whole body PET-CT EGFR-targeted imaging, ex-vivo EGFR-based PET imaging of the colon, and histopathological findings of the degree of EGFR expression. The visualized weak EGFR staining of healthy colon is likely secondary to the limited EGFR expression in the basolateral surface of the colon²³. We additionally confirmed the previously reported weak EGFR staining for DSS-induced colitis⁴⁷. High EGFR staining was clearly visualized in the CT26 allograft and colorectal adenomas in the GEMM. It has been previously noted that the mean specific EGFR intensity in neoplasia is approximately ten times higher than in normal mucosa¹². Given the high correlation between lesion EGFR expression and uptake of the developed ⁶⁴Cu-DOTA-F(ab')₂ PET imaging probe, the approach may be useful not only for detection, but also for anti-EGFR treatment monitoring.

Conclusions

A clinically translatable ⁶⁴Cu-DOTA-cetuximab-F(ab')₂ PET imaging probe was successfully developed to assess EGFR noninvasively. The imaging agent can detect colonic tumors with a high target to background ratio in the setting of colitis. This approach offers improved imaging characteristics compared to standard ¹⁸F-FDG PET imaging for detection of in situ lesions in the setting of IBD, and opens the possibility for a new approach for screening high-risk patients for the development of CRC in the setting of colonic inflammation.

Acknowledgements

This study was supported by U01CA084301, P50CA127003, and U01CA143056. N. Selcan Turker supported by the Dubai Harvard Foundation for Medical Research (DHFMR, grant number: 223439).

Competing Interests

The authors have declared that no competing interest exists.

References

- Lissner D, Siegmund B. Ulcerative colitis: current and future treatment strategies. *Dig Dis* 2013;31:91-4.
- Burisch J, Munkholm P. Inflammatory bowel disease epidemiology. *Curr Opin Gastroenterol* 2013;29:357-62.
- O'Connor OJ, McDermott S, Slattery J, et al. The Use of PET-CT in the Assessment of Patients with Colorectal Carcinoma. *Int J Surg Oncol* 2011;2011:846512.
- Ahmadi A, Polyak S, Draganov PV. Colorectal cancer surveillance in inflammatory bowel disease: the search continues. *World J Gastroenterol* 2009;15:61-6.
- Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. *Gastroenterology* 2003;124:880-8.
- Bernstein CN, Weinstein WM, Levine DS, et al. Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. *Am J Gastroenterol* 1995;90:2106-14.
- Higashikawa K, Akada N, Yagi K, et al. Exploration of target molecules for molecular imaging of inflammatory bowel disease. *Biochem Biophys Res Commun* 2011;410:416-21.
- Bettenworth D, Reuter S, Hermann S, et al. Translational ¹⁸F-FDG PET/CT imaging to monitor lesion activity in intestinal inflammation. *J Nucl Med* 2013;54:748-55.
- Berthold LD, Steiner D, Scholz D, et al. Imaging of chronic inflammatory bowel disease with ¹⁸F-FDG PET in children and adolescents. *Klin Padiatr* 2013;225:212-7.
- Perlman SB, Hall BS, Reichelderfer M. PET/CT imaging of inflammatory bowel disease. *Semin Nucl Med* 2013;43:420-6.
- Mahmood U. Optical molecular imaging approaches in colorectal cancer. *Gastroenterology* 2010;138:419-22.
- Goetz M, Ziebart A, Foersch S, et al. In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. *Gastroenterology* 2010;138:435-46.
- Heinemann V, Stintzing S, Kirchner T, et al. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. *Cancer Treat Rev* 2009;35:262-71.

14. Hoetker MS, Kiesslich R, Diken M, et al. Molecular in vivo imaging of gastric cancer in a human-murine xenograft model: targeting epidermal growth factor receptor. *Gastrointest Endosc* 2012;76:612-20.
15. Dube PE, Yan F, Punit S, et al. Epidermal growth factor receptor inhibits colitis-associated cancer in mice. *J Clin Invest* 2012;122:2780-92.
16. Wong KJ, Baidoo KE, Nayak TK, et al. In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive Cancers. *EJNMMI Res* 2011;1.
17. Cooper MS, Ma MT, Sunassee K, et al. Comparison of (64)Cu-Complexing Bifunctional Chelators for Radioimmunoconjugation: Labeling Efficiency, Specific Activity, and in Vitro/in Vivo Stability. *Bioconjug Chem* 2012.
18. Ferreira CL, Yapp DT, Crisp S, et al. Comparison of bifunctional chelates for (64)Cu antibody imaging. *Eur J Nucl Med Mol Imaging* 2010;37:2117-26.
19. Chan C, Scollard DA, McLarty K, et al. A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. *EJNMMI Res* 2011;1:15.
20. Ferreira CL, Lamsa E, Woods M, et al. Evaluation of Bifunctional Chelates for the Development of Gallium-Based Radiopharmaceuticals. *Bioconjug Chem* 2010.
21. Ferreira CL, Yapp DT, Mandel D, et al. (68)Ga small peptide imaging: comparison of NOTA and PCTA. *Bioconjug Chem* 2012;23:2239-46.
22. Miao Z, Ren G, Liu H, et al. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. *Bioconjug Chem* 2010;21:947-54.
23. Playford RJ, Hanby AM, Gschmeissner S, et al. The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract. *Gut* 1996;39:262-6.
24. Whittam CG, Williams AD, Williams CS. Murine Colitis modeling using Dextran Sulfate Sodium (DSS). *J Vis Exp* 2010.
25. Martin ES, Belmont PJ, Sinnamon MJ, et al. Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. *Clin Cancer Res* 2013;19:2929-40.
26. Hung KE, Maricevich MA, Richard LG, et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. *Proc Natl Acad Sci U S A* 2010;107:1565-70.
27. Kucherlapati MH, Lee K, Nguyen AA, et al. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. *Gastroenterology* 2010;138:993-1002 e1.
28. Kuraguchi M, Wang XP, Bronson RT, et al. Adenomatous polyposis coli (APC) is required for normal development of skin and thymus. *PLoS Genet* 2006;2:e146.
29. Fujii S, Fujimori T, Kawamata H, et al. Development of colonic neoplasia in p53 deficient mice with experimental colitis induced by dextran sulphate sodium. *Gut* 2004;53:710-6.
30. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001;48:526-35.
31. Assadsangabi A, Lobo AJ. Diagnosing and managing inflammatory bowel disease. *Practitioner* 2013;257:13-8, 2.
32. Liu S, Li D, Park R, et al. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies. *J Nucl Med* 2013;54:1094-100.
33. Heskamp S, van Laarhoven HW, Molkenboer-Kuening JD, et al. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507. *Mol Pharm* 2012;9:2314-21.
34. Tang Y, Wang J, Scollard DA, et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. *Nucl Med Biol* 2005;32:51-8.
35. Mahmood U. MICoE Task Force Looks to the Future. *J Nucl Med* 2009;50:15N.
36. Cho IH, Han EO, Kim ST. Very different external radiation doses in patients undergoing PET/CT or PET/MRI scans and factors affecting them. *Hell J Nucl Med* 2014;17:13-8.
37. Zhang Y, Hong H, Orbay H, et al. PET imaging of CD105/endoglin expression with a (6)(1)/(6)(4)Cu-labeled Fab antibody fragment. *Eur J Nucl Med Mol Imaging* 2013;40:759-67.
38. Vlasak J, Ionescu R. Fragmentation of monoclonal antibodies. *MAbs* 2011;3:253-63.
39. Sihver W, Pietzsch J, Krause M, et al. Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy. *Pharmaceuticals (Basel)* 2014;7:311-38.
40. Tang Y, Scollard D, Chen P, et al. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments. *Nucl Med Commun* 2005;26:427-32.
41. Cai W, Chen K, He L, et al. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. *Eur J Nucl Med Mol Imaging* 2007;34:850-8.
42. Kulendran M, Stebbing JF, Marks CG, et al. Predictive and prognostic factors in colorectal cancer: a personalized approach. *Cancers (Basel)* 2011;3:1622-38.
43. Machin P, Catusas L, Pons C, et al. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome. *J Cutan Pathol* 2002;29:415-20.
44. Svrcek M, Cosnes J, Tiret E, et al. Expression of epidermal growth factor receptor (EGFR) is frequent in inflammatory bowel disease (IBD)-associated intestinal cancer. *Virchows Arch* 2007;450:243-4.
45. Rego RL, Foster NR, Smyrk TC, et al. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. *Br J Cancer* 2010;102:165-72.
46. Spano JP, Lagorce C, Atlan D, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. *Ann Oncol* 2005;16:102-8.
47. Alexander RJ, Panja A, Kaplan-Liss E, et al. Expression of growth factor receptor-encoded mRNA by colonic epithelial cells is altered in inflammatory bowel disease. *Dig Dis Sci* 1995;40:485-94.